Cargando…
Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes
OBJECTIVE: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of ani...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358538/ https://www.ncbi.nlm.nih.gov/pubmed/30545741 http://dx.doi.org/10.1016/j.molmet.2018.11.008 |
_version_ | 1783392009362341888 |
---|---|
author | Aghanoori, Mohamad-Reza Smith, Darrell R. Shariati-Ievari, Shiva Ajisebutu, Andrew Nguyen, Annee Desmond, Fiona Jesus, Carlos H.A. Zhou, Xiajun Calcutt, Nigel A. Aliani, Michel Fernyhough, Paul |
author_facet | Aghanoori, Mohamad-Reza Smith, Darrell R. Shariati-Ievari, Shiva Ajisebutu, Andrew Nguyen, Annee Desmond, Fiona Jesus, Carlos H.A. Zhou, Xiajun Calcutt, Nigel A. Aliani, Michel Fernyhough, Paul |
author_sort | Aghanoori, Mohamad-Reza |
collection | PubMed |
description | OBJECTIVE: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of animal models of type 1 and type 2 diabetes. We hypothesized that sub-optimal insulin-like growth factor 1 (IGF-1) signaling in diabetes drives loss of AMPK activity and mitochondrial function, both contributing to development of DSPN. METHODS: Age-matched control Sprague-Dawley rats and streptozotocin (STZ)-induced type 1 diabetic rats with/without IGF-1 therapy were used for in vivo studies. For in vitro studies, DRG neurons from control and STZ-diabetic rats were cultured and treated with/without IGF-1 in the presence or absence of inhibitors or siRNAs. RESULTS: Dysregulation of mRNAs for IGF-1, AMPKα2, ATP5a1 (subunit of ATPase), and PGC-1β occurred in DRG of diabetic vs. control rats. IGF-1 up-regulated mRNA levels of these genes in cultured DRGs from control or diabetic rats. IGF-1 treatment of DRG cultures significantly (P < 0.05) increased phosphorylation of Akt, P70S6K, AMPK and acetyl-CoA carboxylase (ACC). Mitochondrial gene expression and oxygen consumption rate (spare respiratory capacity), ATP production, mtDNA/nDNA ratio and neurite outgrowth were augmented (P < 0.05). AMPK inhibitor, Compound C, or AMPKα1-specific siRNA suppressed IGF-1 elevation of mitochondrial function, mtDNA and neurite outgrowth. Diabetic rats treated with IGF-1 exhibited reversal of thermal hypoalgesia and, in a separate study, reversed the deficit in corneal nerve profiles. In diabetic rats, IGF-1 elevated the levels of AMPK and P70S6K phosphorylation, raised Complex IV-MTCO1 and Complex V-ATP5a protein expression, and restored the enzyme activities of Complex IV and I in the DRG. IGF-1 prevented TCA metabolite build-up in nerve. CONCLUSIONS: In DRG neuron cultures IGF-1 signals via AMPK to elevate mitochondrial function and drive axonal outgrowth. We propose that this signaling axis mediates IGF-1-dependent protection from distal dying-back of fibers in diabetic neuropathy. |
format | Online Article Text |
id | pubmed-6358538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63585382019-02-07 Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes Aghanoori, Mohamad-Reza Smith, Darrell R. Shariati-Ievari, Shiva Ajisebutu, Andrew Nguyen, Annee Desmond, Fiona Jesus, Carlos H.A. Zhou, Xiajun Calcutt, Nigel A. Aliani, Michel Fernyhough, Paul Mol Metab Original Article OBJECTIVE: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of animal models of type 1 and type 2 diabetes. We hypothesized that sub-optimal insulin-like growth factor 1 (IGF-1) signaling in diabetes drives loss of AMPK activity and mitochondrial function, both contributing to development of DSPN. METHODS: Age-matched control Sprague-Dawley rats and streptozotocin (STZ)-induced type 1 diabetic rats with/without IGF-1 therapy were used for in vivo studies. For in vitro studies, DRG neurons from control and STZ-diabetic rats were cultured and treated with/without IGF-1 in the presence or absence of inhibitors or siRNAs. RESULTS: Dysregulation of mRNAs for IGF-1, AMPKα2, ATP5a1 (subunit of ATPase), and PGC-1β occurred in DRG of diabetic vs. control rats. IGF-1 up-regulated mRNA levels of these genes in cultured DRGs from control or diabetic rats. IGF-1 treatment of DRG cultures significantly (P < 0.05) increased phosphorylation of Akt, P70S6K, AMPK and acetyl-CoA carboxylase (ACC). Mitochondrial gene expression and oxygen consumption rate (spare respiratory capacity), ATP production, mtDNA/nDNA ratio and neurite outgrowth were augmented (P < 0.05). AMPK inhibitor, Compound C, or AMPKα1-specific siRNA suppressed IGF-1 elevation of mitochondrial function, mtDNA and neurite outgrowth. Diabetic rats treated with IGF-1 exhibited reversal of thermal hypoalgesia and, in a separate study, reversed the deficit in corneal nerve profiles. In diabetic rats, IGF-1 elevated the levels of AMPK and P70S6K phosphorylation, raised Complex IV-MTCO1 and Complex V-ATP5a protein expression, and restored the enzyme activities of Complex IV and I in the DRG. IGF-1 prevented TCA metabolite build-up in nerve. CONCLUSIONS: In DRG neuron cultures IGF-1 signals via AMPK to elevate mitochondrial function and drive axonal outgrowth. We propose that this signaling axis mediates IGF-1-dependent protection from distal dying-back of fibers in diabetic neuropathy. Elsevier 2018-11-28 /pmc/articles/PMC6358538/ /pubmed/30545741 http://dx.doi.org/10.1016/j.molmet.2018.11.008 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Aghanoori, Mohamad-Reza Smith, Darrell R. Shariati-Ievari, Shiva Ajisebutu, Andrew Nguyen, Annee Desmond, Fiona Jesus, Carlos H.A. Zhou, Xiajun Calcutt, Nigel A. Aliani, Michel Fernyhough, Paul Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
title | Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
title_full | Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
title_fullStr | Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
title_full_unstemmed | Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
title_short | Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
title_sort | insulin-like growth factor-1 activates ampk to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358538/ https://www.ncbi.nlm.nih.gov/pubmed/30545741 http://dx.doi.org/10.1016/j.molmet.2018.11.008 |
work_keys_str_mv | AT aghanoorimohamadreza insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT smithdarrellr insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT shariatiievarishiva insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT ajisebutuandrew insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT nguyenannee insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT desmondfiona insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT jesuscarlosha insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT zhouxiajun insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT calcuttnigela insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT alianimichel insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes AT fernyhoughpaul insulinlikegrowthfactor1activatesampktoaugmentmitochondrialfunctionandcorrectneuronalmetabolisminsensoryneuronsintype1diabetes |